Researchers at the University of Michigan (U-M) School of Pharmacy and the Rogel Cancer Center took a different approach to boosting the STING pathway. The team observed that adding the nutritional metal ion manganese to STING agonists boosted STING’s tumor-fighting capability.
Their findings are published in the journal Nature Nanotechnology in a paper titled, “Amplifying STING activation by cyclic dinucleotide–manganese particles for local and systemic cancer metalloimmunotherapy.”
“Nutritional metal ions play critical roles in many important immune processes,” the researchers wrote. “Hence, the effective modulation of metal ions may open up new forms of immunotherapy, termed as metalloimmunotherapy.”
The researchers observed that adding the nutritional metal ion manganese to STING agonists boosted STING’s tumor-fighting capability up to 77-fold, compared to STING agonists used alone, explained James Moon, the J.G. Searle professor of pharmaceutical sciences and of biomedical engineering.
Most STING agonists must be delivered directly into the tumor, but this isn’t suitable for metastatic cancers, a major cause of mortality. To develop a STING agonist for intravenous administration, the researchers coated these nanocrystals with a lipid layer (similar to those found in mRNA COVID-19 vaccines), resulting in a nanoparticle system called CMP.
“CMP significantly increases cellular uptake of STING agonists, and together with manganese, CMP triggers robust STING activation,...
Read Full Story: https://www.genengnews.com/news/novel-approach-for-intravenous-cancer-immunotherapy/
Your content is great. However, if any of the content contained herein violates any rights of yours, including those of copyright, please contact us immediately by e-mail at media[@]kissrpr.com.
